Submitted by mrhodes40 on Fri, 2007-05-25 11:17

Mult Scler. 2007 May;13(4):517-26. Epub 2007 Feb 9.
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW.
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

Minocycline has immunomodulatory and neuroprotective activities in vitro and in an animal model of multiple sclerosis (MS). We have previously reported that minocycline decreased gadolinium-enhancing activity over six months in a small trial of patients with active relapsing-remitting MS (RRMS). Here we report the impact of oral minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in this cohort over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment annualized relapse rate (1.3/year pre-enrolment; 1.2/year during a three-month baseline period) prior to treatment, no relapses occurred between months 6 and 24. Also, despite very active MRI activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of the p40 subunit of interleukin (IL)-12, which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1. The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS. Multiple Sclerosis 2007; 13: 517-526.

PMID: 17463074 [PubMed - in process]
This study draws the conclusion that immunomodulation is the cause of the positive effect of minocycline on MS (see the title!), but since the belief of the researchers is that MS is an immune system disease they were not looking at or for bacteria like CPn.


Well now, that is very interesting & done right in my home province Alberta, Canada!!The neurologist I saw when asked told me there was nooo bacterial connection with MS & she hasn't been out of "school" that long, she is young & brain washed, lol.With Christ in FaithRuth 

CFIDS/ME, FMS, MCS, IBS, EBV, CMV, Cpn, H1, chronic insomnia, Chronic Lyme, HME, Babesia, Natural HRT-menopause, NAC 2.4 gm,Full CAP 6-2-07, all supplements+Iodorol, Inositol-depression, ultra Chitosan, L lysine Pulse#27 04-19-10 1gm Flagyl/day-5 days<

Well this work is on minocycline and how it impacted people with MS and since it had a positive effect it was determined that the effect was due to the fact that minocylcline damps down the immune system in a specific way: the matrix mettaloproteinases, IL-12, adhesion molecules were all impacted by treatment in a way that "would" presumably dampen down autoimmunity. This study if seen by a neurologist would support the autoimmune theory in their minds sadly. but it does give one added reason to partake... Coolmarie On CAP since Sept '05 for MS, RA, Asthma, sciatica. EDSS at start 5.5. Currently on: Doxy 200, Azith 3x week, Tini cont. since April '07, all supplements. "Color out side the lines!"

On CAP since Sept '05 for MS, RA, Asthma, sciatica. EDSS at start 5.5.(early cane) Now 6 (cane full time) Originally on: Doxy 200, Azith 3x week, Tini cont. over summer '07, Revamp of protocol in Summer '08 by Stratton due to functional loss; clarithro

That both minocycline and doxycycline are immunomodulatory is without doubt: I took doxycycline and roxithromycin for six months then changed the doxycycline for rifampicin, not immunomodalating at all, and I certainly felt the difference for a few weeks, however, I would not have made my improvements just because of the immunomodulating.  These things take time, but as soon as the non-antibiotic minocycline comes on the market people should start to see the difference. Well, one lives in hopeUndecided...........Sarah   An Itinerary in Light and ShadowStratton/Wheldon regime since August 2003, for very aggressive SPMS.  Intermittent therapy after one year. 2007 still take this, now two weeks every three months, but still slowly improving and no exacerbation since starting. EDSS was about 7, now 2.

Completed Stratton/Wheldon regime for aggressive secondary progressive MS in June 2007, after four years, three of which intermittent.   Still improving bit by bit and no relapses since finishing treatment.